"ddI Trials Recruiting"

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

"ddI Trials Recruiting"

Bay Area Reporter (12/21/89) Vol. 19, No. 51, P. 20
Hafs, Etienne

Abstract: The National Institute of Allergy and Infectious Diseases (NIAID) has begun recruiting volunteers for a study of dideoxyinosine (ddI), a member of a promising group of anti-HIV drugs called nucleoside analogues. DDI does not affect already-infected cells, but inhibits HIV replication and reduces the rate at which cells become infected with the virus. NIAID's AIDS Clinical Trials Group is recruiting for three Phase II and Phase III trials of the drug, alone and in combination with AZT. About 2600 people will take part in the trials. An additional 5000 patients who need the drug but do not qualify for the trials will receive the drug free from drug maker Bristol-Myers. Information about the ddI protocols is available by calling 1-800-874-2572. In early studies, people with AIDS or ARC who took ddI at higher doses showed signs of improved immune system functions and reported increased energy and appetite. Some patients taking ddI have reported peripheral neuropathy, pain or numbness in the hands and feet.

891221
AD890047

Copyright © 1989 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.